Results 71 to 80 of about 58,504 (176)

Evaluation of pomegranate rind (Punica granatum) hydroethanolic extract on blood parameters in male mice treated by Irinotecan Hcl

Armaghane Danesh Bimonthly Journal, 2015
Background & aim: Irinotecan Hcl is the first order drug for some neoplasm treatment in patients. Irinotecan Hcl has side effects on blood such as anemia and leukopeny.
N Mirazi, Sh Nosrati, A Hosseini
doaj  

ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia [PDF]

, 2016
Neutropenia is a common dose-limiting toxicity associated with irinotecan treatment. Although UGT1A1 variants have been associated with neutropenia, a fraction of neutropenia risk remains unaccounted for.
Baldwin, R M, Li, M, Seiser, E L, Ramirez, J, Ratain, M J, Kroetz, D L, Innocenti, F   +6 more
core   +1 more source

Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer

Cancer Treatment and Research Communications
Purpose: There is evidence that adding cetuximab can overcome resistance to irinotecan, but a similar analysis with Panitumumab isn't readily available. This study evaluated the activity of each anti-EGFR plus irinotecan as a salvage third-line treatment
Maria Ignez Freitas Melro Braghiroli, Daniel Santos Rocha Sobral Filho, Juliana Goes Martins Fagundes, Elizabeth Zambrano Mendoza, Maria Fernanda Batistuzzo Vicentini Neffa, Karla Souza Campos, Leonardo Gomes da Fonseca, Renata Colombo Bonadio, Aley Talans, Oddone Freitas Melro Braghiroli, Maria Cecília Mathias-Machado, Jorge Sabbaga, Camila Motta Venchiarutti Moniz, Paulo Marcelo Gehm Hoff   +13 more
doaj   +1 more source

Renal function as a predictor of irinotecan-induced neutropenia

, 2008
Although approximately half of the administered dose of irinotecan is recovered in urine, scarce data are available on the association of renal function with irinotecan pharmacokinetics and toxicity.
de Jong, FA (Floris), Bol, Jessica, Gelder, Teun, Mathijssen, RHJ; id_orcid, Sparreboom, A, Wiemer, Erik; id_orcid, Verweij, Jaap   +6 more
core   +1 more source

Rifaximin alleviates irinotecan-induced diarrhea in mice model

Annals of Medicine
Background Irinotecan is a chemotherapeutic drug widely used to treat solid tumors. However, its effectiveness is limited by the severely delayed onset of diarrhea.
Chengyi Huang, Huiyin Lan, Minghua Bai, Jinggang Chen, Shengkun Xu, Quanquan Sun, Qianping Chen, Wei Mao, Jin Jiang, Ji Zhu   +9 more
doaj   +1 more source

Successful Desensitization to Irinotecan in a Patient with Metastatic Esophageal Squamous Cell Carcinoma and a History of Anaphylaxis in Response to Irinotecan—Case Report and Literature Review

Background: Irinotecan is a topoisomerase I inhibitor used for the treatment of various cancers, such as gastrointestinal, pancreatic, pulmonary, ovarian, and cervical cancers.
Radu Serescu, Bumbăcea, Roxana Silvia, Nedelcu, Denisa-Mihaela, Selda Ali, Denisa-Mihaela Nedelcu, Roxana Silvia Bumbăcea, Serescu, Radu, Ali, Selda   +7 more
core   +1 more source

Supplementary Material for: Irinotecan-Induced Dysarthria

, 2017
Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease. Here, we describe the case of a 46-year-old patient with metastatic rectal carcinoma who received second ...
van der Vliet H.J. (4131472), van der Mijn J.C. (4131481), Aalders I.J. (4131484), Dressel A.J. (4131475), Rinkel R.N.P.M. (4131478)   +4 more
core   +1 more source

Irinotecan

Revista de Medicina de la Universidad de Navarra, 2017
Gil, I. (Iñigo), Honorato, J. (Jesús), Cárdenas, E. (E.)   +2 more
  +7 more sources

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance

, 2020
Aims. We here investigated whether the combination of simvastatin and irinotecan could induce the synergistic effect on colon cancer cells with or without resistance to irinotecan. Methods. We investigated cell proliferation assay and assessed cell death
Hyun Joo Jang, Juah Jang, Eun Mi Hong, Hyun Woo Byun, Sea Hyub Kae, Se Woo Park, Jung Eun Choi, Jin Lee, Min Ho Choi, Dong Hee Koh   +9 more
core  

Population pharmacokinetics of intraperitoneal irinotecan and SN‐38 in patients with peritoneal metastases from colorectal origin

CPT: Pharmacometrics & Systems Pharmacology
Peritoneal metastases (PM) are common in patients with colorectal cancer. Patients with PM have a poor prognosis, and for those who are not eligible for cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC ...
Pascale C. S. Rietveld, Sebastiaan D. T. Sassen, Niels A. D. Guchelaar, Ruben A. G. vanEerden, Nadine L. deBoer, Teun B. M. van denHeuvel, Jacobus W. A. Burger, Ron H. J. Mathijssen, Birgit C. P. Koch, Stijn L. W. Koolen   +9 more
doaj   +1 more source